Monitoring proteinase 3 antineutrophil cytoplasmic antibodies for detection of relapses in small vessel vasculitis
- PMID: 12965902
- PMCID: PMC193911
- DOI: 10.1128/cdli.10.5.769-774.2003
Monitoring proteinase 3 antineutrophil cytoplasmic antibodies for detection of relapses in small vessel vasculitis
Abstract
The clinical usefulness of antineutrophil cytoplasmic antibodies (ANCAs) in the monitoring of patients treated for small vessel vasculitis is debated. A capture enzyme-linked immunosorbent assay (ELISA) based on anti-proteinase 3 (anti-PR3) monoclonal antibody 4A3 has previously been proven to be superior to indirect immunofluorescence (IIF) and standard ELISA for the diagnosis of vasculitis. The present study compared the effectiveness of the capture ELISA for the detection of disease relapse. Samples from patients with relapses and remissions (relapse and remission samples, respectively) were identified through the database of the Glomerular Disease Collaborate Network. Twenty-one relapse samples and 49 remission samples were analyzed by the capture PR3-ANCA ELISA from Wieslab AB, the standard PR3-ANCA ELISA from Inova, and IIF. A Medline search was performed to identify published data on ANCA status at relapse. The capture ELISA was positive for 21 instances of relapses in 14 patients, while the standard ELISA and IIF each failed to detect 2 relapses (P was not significant). By using a higher cutoff value, the capture ELISA correctly categorized 84% of the remission samples and 81% of the relapse samples. Similar degrees of discrimination could be achieved by IIF but not by the standard ELISA. In previously published series, the median proportions of patients positive at relapse were 100% by IIF (range, 75 to 100%) and 86% by standard ELISA (range, 38 to 100%). The corresponding values for a rise that accompanied or preceded a relapse were 75% (range, 20 to 100%) for IIF and 50% (range, 25 to 81%) for ELISA. The capture PR3-ANCA ELISA is a sensitive tool for the detection of relapses. Larger studies are needed to detect differences between methods. Negative results by tests for ANCAs are rare during relapses.
Figures


Similar articles
-
Clinical evaluation of a capture ELISA for detection of proteinase-3 antineutrophil cytoplasmic antibody.Kidney Int. 1998 May;53(5):1230-6. doi: 10.1046/j.1523-1755.1998.00873.x. Kidney Int. 1998. PMID: 9573537
-
Diagnostic value of standardized assays for anti-neutrophil cytoplasmic antibodies in idiopathic systemic vasculitis. EC/BCR Project for ANCA Assay Standardization.Kidney Int. 1998 Mar;53(3):743-53. doi: 10.1046/j.1523-1755.1998.00807.x. Kidney Int. 1998. PMID: 9507222
-
Comparison of anti-PR3 capture and anti-PR3 direct ELISA for detection of antineutrophil cytoplasmic antibodies (ANCA) in long-term clinical follow-up of PR3-ANCA-associated vasculitis patients.Clin Nephrol. 2001 Oct;56(4):295-301. Clin Nephrol. 2001. PMID: 11680659
-
Diagnostic accuracy of antineutrophil cytoplasmic antibodies (ANCA) in predicting relapses of ANCA-associated vasculitis: systematic review and meta-analysis.Rheumatol Int. 2023 Mar;43(3):437-448. doi: 10.1007/s00296-022-05192-3. Epub 2022 Aug 30. Rheumatol Int. 2023. PMID: 36040492
-
International Consensus Statement on Testing and Reporting of Antineutrophil Cytoplasmic Antibodies (ANCA).Am J Clin Pathol. 1999 Apr;111(4):507-13. doi: 10.1093/ajcp/111.4.507. Am J Clin Pathol. 1999. PMID: 10191771 Review.
Cited by
-
Value of ANCA measurements during remission to predict a relapse of ANCA-associated vasculitis--a meta-analysis.Rheumatology (Oxford). 2012 Jan;51(1):100-9. doi: 10.1093/rheumatology/ker280. Epub 2011 Oct 29. Rheumatology (Oxford). 2012. PMID: 22039267 Free PMC article.
-
IgA- and SIgA anti-PR3 antibodies in serum versus organ involvement and disease activity in PR3-ANCA-associated vasculitis.Clin Exp Immunol. 2016 May;184(2):208-15. doi: 10.1111/cei.12769. Epub 2016 Feb 25. Clin Exp Immunol. 2016. PMID: 26762653 Free PMC article.
-
An approach to the diagnosis and management of systemic vasculitis.Clin Exp Immunol. 2010 May;160(2):143-60. doi: 10.1111/j.1365-2249.2009.04078.x. Epub 2010 Jan 12. Clin Exp Immunol. 2010. PMID: 20070316 Free PMC article. Review.
-
Do Relapses Follow ANCA Rises? A Systematic Review and Meta-Analysis on the Value of Serial ANCA Level Evaluation.Front Med (Lausanne). 2022 Jul 4;9:844112. doi: 10.3389/fmed.2022.844112. eCollection 2022. Front Med (Lausanne). 2022. PMID: 35860735 Free PMC article.
-
Renal involvement in Wegener's granulomatosis.Clin Rev Allergy Immunol. 2008 Oct;35(1-2):22-9. doi: 10.1007/s12016-007-8066-6. Clin Rev Allergy Immunol. 2008. PMID: 18172777 Review.
References
-
- Arranz, O., J. Ara, R. Rodriguez, L. Quinto, J. Font, E. Mirapeix, and A. Darnell. 2001. Comparison of anti-PR3 capture and anti-PR3 direct ELISA for detection of antineutrophil cytoplasmic antibodies (ANCA) in long-term clinical follow-up of PR3-ANCA-associated vasculitis patients. Clin. Nephrol. 56:295-301. - PubMed
-
- Boomsma, M. M., C. A. Stegeman, M. J. van der Leij, W. Oost, J. Hermans, C. G. Kallenberg, P. C. Limburg, and J. W. Cohen Tervaert. 2000. Prediction of relapses in Wegener's granulomatosis by measurement of antineutrophil cytoplasmic antibody levels: a prospective study. Arthritis Rheum. 43:2025-2033. - PubMed
-
- Cohen, L. H., C. B. Wilson, and R. M. Freeman. 1976. Goodpasture syndrome: recovery after severe renal insufficiency. Arch. Intern. Med. 136:835-837. - PubMed
-
- Cohen Tervaert, J. W., M. G. Huitema, R. J. Hene, W. J. Sluiter, T. H. The, G. K. van der Hem, and C. G. Kallenberg. 1990. Prevention of relapses in Wegener's granulomatosis by treatment based on antineutrophil cytoplasmic antibody titre. Lancet 336:709-711. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical